YOLFTbeta
Passage Bio Inc

Passage Bio Inc

PASG · NASDAQ · Healthcare / Biotechnology

4.25USD+0.24 (+5.99%)

Price History

Full chart

Market Stats

Previous Close4.01
Open3.95
Day Range3.95 – 4.25
52-Week Range3.29 – 20.00
Volume11.93K
Market Cap15.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-11.32
Dividend Yield0.00%
Beta1.43
50-Day Avg4.67
200-Day Avg7.31

About

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. William Chou M.D., Ph.D.
  • Employees24
  • HeadquartersOne Commerce Square, Philadelphia, PA, United States, 19103, USA
  • Websitehttps://www.passagebio.com

Leadership

  • Dr. William Chou M.D., Ph.D.President, CEO & Director · b. 1973
  • Ms. Kathleen BorthwickSenior VP, CFO, Principal Financial Officer & Principal Accounting Officer · b. 1977

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000
Cost of Revenue-134.00K800.00K1.54M3.68M3.72M3.08M728.00K
Gross Profit--134.00K-800.00K-1.54M-3.68M-3.72M-3.08M-728.00K
Operating Expense-37.05M112.10M184.19M134.72M96.42M67.32M42.42M
Operating Income-13.47M-37.19M-112.90M-185.73M-138.39M-100.14M-70.40M-43.15M
EBITDA-7.42M-36.55M-111.10M-176.19M-131.72M-98.34M-62.09M-44.79M
Net Income-12.77M-45.63M-112.23M-185.39M-136.13M-102.06M-64.77M-45.52M
R&D9.17M30.24M82.79M117.67M86.05M59.56M40.18M23.28M
Interest Expense696.00K8.45M670.00K343.00K2.27M---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets33.46M178.61M328.01M355.08M243.55M150.54M102.41M62.28M
Total Liabilities45.63M4.26M23.29M36.42M42.18M39.26M41.15M43.53M
Total Equity-12.17M174.35M304.71M318.66M201.37M111.28M61.26M18.75M
Cash24.86M158.87M135.00M128.97M34.60M21.71M37.57M46.30M
Total Debt----27.11M26.29M25.48M24.01M
Net Debt-24.86M-158.87M-135.00M-128.97M-7.49M4.58M-12.10M-22.29M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.57M-39.90M-80.52M-126.88M-118.21M-78.26M-47.96M-31.51M
Investing Cash Flow-2.54M-1.69M-172.11M-45.81M25.20M65.24M54.95M40.22M
Financing Cash Flow45.97M175.60M228.75M166.66M-1.35M135.00K8.87M23.00K
Capital Expenditure2.54M1.69M1.65M25.64M5.27M146.00K34.00K0
Free Cash Flow-21.11M-41.59M-82.17M-152.52M-123.48M-78.41M-47.99M-31.51M
FCF to OCF113.70%104.24%102.04%120.21%104.46%100.19%100.07%100.00%

Earnings

Report DateFeb 28, 2020May 11, 2020Aug 13, 2020Nov 10, 2020Mar 3, 2021May 5, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 16, 2022Aug 4, 2022Nov 10, 2022Mar 6, 2023May 11, 2023Aug 7, 2023Nov 13, 2023Mar 4, 2024May 14, 2024Aug 8, 2024Nov 13, 2024Mar 3, 2025May 13, 2025Aug 12, 2025Nov 10, 2025Mar 3, 2026May 19, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate-0.69-9.55-10.35-13.35-0.70-14.14-15.15-17.40-0.89-18.38-15.93-15.44-0.52-10.15-9.55-8.80-0.40-6.90-6.20-4.67-0.20-4.47-4.15-2.97-2.80-3.06-2.20-2.16
EPS Actual-0.69-7.76-12.00-12.60-0.85-15.20-18.00-17.40-0.95-15.80-14.60-9.80-0.49-12.60-8.80-7.93-0.30-6.00-5.20-4.71-0.20-5.00-2.96-2.44-4.09-2.36-2.44-
Surprise0.00%18.74%-15.94%5.62%-21.43%-7.50%-18.81%0.00%-6.74%14.04%8.35%36.53%5.77%-24.14%7.85%9.89%25.00%13.04%16.13%-0.86%0.00%-11.86%28.67%17.85%-46.07%22.89%-10.91%-
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hours-Pre-market-

Key Statistics & Ratios

Market Cap15.04M
Enterprise Value-8.07M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.61
EPS-11.32
Book Value1.39
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-37.58M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-169.09%
Return on Assets-45.62%
Shares Outstanding3.22M
Shares Float3.20M
Beta1.43
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 15.50
  • Strong Buy
    5

Ownership Breakdown

Institutions
46.44%
Insiders
7.71%
Retail / Other
45.85%

Top Institutional Holders

  • Lynx1 Capital Management, LP
    673.76K20.94%
  • Vestal Point Capital LP
    305.00K9.48%
  • Renaissance Technologies Corp
    133.61K4.15%
  • Vanguard Capital Management, LLC
    113.96K3.54%
  • Yiheng Capital LLC
    86.10K2.68%
  • Erste Asset Management GmbH
    85.26K2.65%
  • Ikarian Capital, LLC
    68.12K2.12%
  • Geode Capital Management, LLC
    41.38K1.29%
  • Verdad Advisers, LP
    30.73K0.95%
  • BlackRock Inc
    28.59K0.89%
  • UBS Group AG
    27.50K0.85%
  • Acadian Asset Management LLC
    24.20K0.75%
  • BOOTHBAY FUND MANAGEMENT, LLC
    18.87K0.59%
  • Vanguard Fiduciary Trust Co
    17.05K0.53%
  • Deltec Asset Management LLC
    15.00K0.47%
  • XTX Topco Ltd
    12.63K0.39%
  • Fiduciary Trust Co
    10.75K0.33%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    78.76K2.45%
  • Fidelity Extended Market Index
    17.13K0.53%
  • Abante Quant Value FI
    14.15K0.44%

Stock Splits

  • Jul 14, 20251:20